Trial Profile
Phase II study of amikacin in cystic fibrosis patients with nontuberculous mycobacterial infections
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2021
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Nontuberculous mycobacterium infections
- Focus Therapeutic Use
- 21 Oct 2021 According to an Matinas BioPharma Media release, the company expects to initiate this study by the first quarter of 2023, following required longer-term preclinical toxicology studies to be conducted during 2022.
- 10 May 2021 According to an Matinas BioPharma Media release, the company expects to initiate this trial in 2022.
- 20 Dec 2020 According to a Matinas BioPharma media release, the Cystic Fibrosis Foundation (CFF) has indicated to the company a willingness to consider a request for monetary support for the continuation of clinical studies, including dose determination and Phase 2 efficacy studies in CF patients suffering from NTM lung disease.